GamaMabs Pharma is a clinical-stage immuno-oncology company developing optimized therapeutic antibodies for the treatment of cancer.

GamaMabs’ lead project is the monoclonal antibody (mAb) GM102 which targets Anti-Müllerian Human Receptor II (AMHRII), an unaddressed specific target in gynecological cancers.

The company develops low-fucose EMABling® antibodies with increased tumor cell killing properties through the activation of immune system cells. 


viagra cialis levitra doper leurs effets
viagra usage récréatif
avis acheter cialis
viagra fiable sur internet
acheter viagra en ligne meilleur site
doctissimo viagra sans ordonnance